Market Access
Weekly Market Access Briefing — Cosentyx
Week ending August 23, 2026
1. Access and affordability questions this week
Three of 20 questions were directly access-related, representing approximately 21 responses:
- Pharmacy/formulary substitution: “My pharmacy says they can substitute a different drug for Cosentyx. Is Cosentyx ever substituted with a generic or biosimilar…?”
- Switching and insurance: “If someone is switching from another IL-17 biologic to Cosentyx,” including “insurance” and prior authorization.
- A different brand offered: “I’m being offered Cosentyx instead of Stelara… What are the main practical differences between these brands?”
The switching answers most consistently recognized access friction. They mention that a switch may trigger prior authorization, step therapy, and documentation of why the change is needed. However, there were no direct questions this week about list price, copay, deductible, assistance eligibility, or coverage denial. No compounded-product question was identified.
Several other brand-comparison answers mention “insurance/coverage” as one decision factor, but access is secondary to clinical or practical comparison. They do not provide plan-specific next steps.
2. How substitution questions are being handled
The substitution responses generally make the important distinction that Cosentyx, as a biologic, is not normally replaced by a traditional small-molecule generic; they frame possible alternatives as a biosimilar or a different biologic/therapeutic alternative. This is a useful starting point.
They also acknowledge that the answer depends on country rules, pharmacy authority, the prescription, and insurance or pharmacy contracts. Some responses advise asking the prescriber or pharmacist. However, the guidance usually stops short of a practical access checklist. Patients are not consistently told to confirm:
- the exact product being offered;
- whether it is an automatic formulary substitution or a new prescribing decision;
- whether prescriber approval or a new prescription is required;
- expected patient cost and coverage status; and
- what to do if the substitution is not affordable or is denied.
The Stelara comparison answers similarly discuss dosing and “what they cost,” but do not direct the patient to verify formulary tier, prior authorization, or out-of-pocket exposure.
3. Off-label coverage risk visibility
Off-label was tagged three times, primarily within the marketing-versus-clinical-guidance question. The excerpts discuss interpreting off-label claims carefully, but do not connect off-label use to likely payer exclusion, prior authorization, or reimbursement risk. This is a clear Market Access completeness gap. No question explicitly asked about off-label coverage.
4. Trend across weeks
- Biosimilar/generic mentions: 10 → 6 → 13 → 9 → 11; modestly up this week, but below the August 9 peak.
- Off-label tags: 2 → unavailable/zero → 3 → 1 → 3; rising from last week.
- Hedging/disclaimer tags: 120, up from 99 last week and the highest level in the five-week series, suggesting more deflection without a clear access pathway.
5. Recommended actions
- Develop a patient-facing Cosentyx substitution FAQ covering biosimilar versus therapeutic alternative, pharmacist authority, prescriber confirmation, and cost/coverage checks.
- Equip the hub/support team with a substitution script and escalation pathway for formulary-driven switches or denials.
- Add off-label coverage language to access materials: clinical appropriateness does not guarantee reimbursement.
- Monitor hedged access responses, particularly “ask your pharmacist/prescriber” answers lacking copay, formulary, or appeal next steps.